Suchergebnisse - "Fernandes, Ancilla W."

PubPharm (67)

1

Tolvaptan and Number Needed to Harm in Autosomal Dominant Polycystic Kidney Disease

enthalten in: Kidney medicine | 2024

von Betts, K. | Nunna, S. | Kumar, R. | +2

2

Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease : a post hoc pooled analysis

enthalten in: BMC nephrology | 2023

von Lioudis, M. | Zhou, X. | Davenport, E. | +4

3

Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis

enthalten in: BMC nephrology | 2023

von Lioudis, M. | Zhou, X. | Davenport, E. | +4

4

Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis

enthalten in: BMC nephrology | 2023

von Lioudis, M. | Zhou, X. | Davenport, E. | +4

5

EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors

enthalten in: BMC cancer | 2020

von Chiang, A. | Fernandes, A. | Pavilack, M. | +5

6

EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors

enthalten in: BMC cancer | 2020

von Chiang, A. | Fernandes, A. | Pavilack, M. | +5

7

EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors

enthalten in: BMC cancer | 2020

von Chiang, A. | Fernandes, A. | Pavilack, M. | +5

8

The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2019

von Subramanian, J. | Fernandes, A. | Laliberté, F. | +3

9

Patient preferences for attributes of tyrosine kinase inhibitor treatments for EGFR mutation-positive non-small-cell lung cancer

enthalten in: Future oncology (London, England) | 2019

von Bridges, J. | la Cruz, M. | Pavilack, M. | +4

10

Treatment patterns and overall survival among patients with unresectable, stage III non-small-cell lung cancer

enthalten in: Future oncology (London, England) | 2019

von Bobbili, P. | Ryan, K. | Duh, M. | +4

1
2
3
4
5
6
7
Nächster »
[7]